• Immunocore Holdings PLC IMCR.OQ reported a quarterly adjusted loss of 20 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -23 cents. The mean expectation of fifteen analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from -51 cents to -5 cents per share.

• Revenue rose 30% to $97.96 million from a year ago; analysts expected $94.77 million.

• Immunocore Holdings PLC's reported EPS for the quarter was a loss of 20 cents​.

• The company reported a quarterly loss of $10.3 million.

• Immunocore Holdings PLC shares had risen by 2.3% this quarter and gained 8.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 18.8% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Immunocore Holdings PLC is $66.00, about 51.4% above its last closing price of $32.10

This summary was machine generated from LSEG data August 7 at 05:16 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)